Medtronic (NYSE:MDT) Given New $95.00 Price Target at Stifel Nicolaus

Medtronic (NYSE:MDT) had its price objective hoisted by stock analysts at Stifel Nicolaus from $80.00 to $95.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “hold” rating on the medical technology company’s stock. Stifel Nicolaus’ price target points to a potential upside of 3.35% from the stock’s current price.

A number of other brokerages have also recently issued reports on MDT. The Goldman Sachs Group reduced their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Robert W. Baird reduced their price target on Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Rothschild & Co Redburn dropped their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Nineteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $102.36.

Medtronic Stock Performance

Medtronic stock opened at $91.92 on Wednesday. The company has a market cap of $117.66 billion, a PE ratio of 24.64, a PEG ratio of 2.43 and a beta of 0.56. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic has a 1 year low of $73.31 and a 1 year high of $106.33. The company’s 50-day moving average is $86.03 and its two-hundred day moving average is $85.42.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts anticipate that Medtronic will post 5.94 earnings per share for the current year.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medtronic

Several institutional investors and hedge funds have recently modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Medtronic during the 2nd quarter worth approximately $4,091,000. First Eagle Investment Management LLC lifted its stake in Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after buying an additional 3,739,288 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Medtronic by 7,655.7% in the second quarter. California State Teachers Retirement System now owns 158,124,578 shares of the medical technology company’s stock valued at $12,370,086,000 after buying an additional 156,085,748 shares during the period. Studio Investment Management LLC boosted its holdings in shares of Medtronic by 15.8% in the second quarter. Studio Investment Management LLC now owns 16,289 shares of the medical technology company’s stock valued at $1,286,000 after buying an additional 2,221 shares during the period. Finally, VELA Investment Management LLC increased its position in shares of Medtronic by 15.7% during the second quarter. VELA Investment Management LLC now owns 7,734 shares of the medical technology company’s stock worth $605,000 after acquiring an additional 1,048 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q1 results exceeded expectations. Medtronic reported adjusted EPS of $1.45 versus the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, topping estimates of approximately $9.55 billion. Growth was broad-based, led by cardiovascular revenue of $3.93 billion, up nearly 19% organically. Medtronic fiscal first-quarter results
• Positive Sentiment: Full-year guidance was raised. Medtronic increased fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00, with management citing strong demand for cardiovascular devices, newer growth platforms and improved margins. Medtronic raises fiscal 2027 forecast
• Positive Sentiment: Robotics expansion strengthens Medtronic’s growth strategy. The company plans to invest approximately $700 million in Hong Kong-based Cornerstone Robotics and obtain rights to distribute its Sentire surgical system in select approved markets outside the U.S. The system will complement Medtronic’s Hugo robotic platform, broadening its minimally invasive surgery offering. Medtronic Cornerstone Robotics partnership
• Positive Sentiment: Additional structural-heart investment supports future products. Medtronic will invest up to $80 million in Pi-Cardia, securing an option to strengthen its technology portfolio for complex transcatheter aortic valve replacement procedures. Analysts at William Blair reiterated a Buy rating, while BTIG raised its price target from $91 to $100.
• Neutral Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus, although full-year guidance remained broadly in line with expectations after the increase.
• Neutral Sentiment: The quarter benefited from an additional fiscal week, which contributed approximately $570 million to organic revenue, creating a comparison factor investors may monitor in coming periods.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).